A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

Colao, Annamaria, Petersenn, Stephan, Newell-Price, John, Findling, James W., Gu, Feng, Maldonado, Mario, Schoenherr, Ulrike, Dipl.-Biol., Mills, David, Salgado, Luiz Roberto, Biller, Beverly M.K.·2012·New England Journal of Medicine
DOI 10.1056/nejmoa1105743

Cited by (625)

Items 101–200 of 625

  1. Current management of Cushing's disease
    Nicholas A. Tritos, Beverly M. K. Biller · 2019 · Journal of Internal Medicine
  2. The Role of Isotretinoin Therapy for Cushing’s Disease: Results of a Prospective Study
    Lúcio Vilar, José Luciano Albuquerque, Ruy Lyra, Erik Trovão Diniz, Frederico Rangel Filho, Patrícia Sampaio Gadelha, Ana Carolina Thé, George Robson Ibiapina, Barbara Sales Gomes, Vera Santos et al. · 2016 · International Journal of Endocrinology
  3. Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples
    Maria Fleseriu, Beverly M. K. Biller · 2022 · Pituitary
  4. Medical Management of Cushing’s Syndrome: Current and Emerging Treatments
    José Miguel Hinojosa‐Amaya, Daniel Cuevas Ramos, Maria Fleseriu · 2019 · Drugs
  5. Therapeutic Strategies for the Treatment of Severe Cushing’s Syndrome
    Krystallenia Alexandraki, Ashley Barry Grossman · 2016 · Drugs
  6. Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma
    Jan Komor, Jean Claude Reubi, Emanuel Christ · 2013 · Pituitary
  7. Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
    Marco Boscaro, Jerome Yves Bertherat, James W. Findling, Maria Fleseriu, A. B. Atkinson, Stephan Petersenn, Jochen Schopohl, Peter J. Snyder, G. Hughes, Andrew Trovato et al. · 2013 · Pituitary
  8. The treatment with pasireotide in Cushing’s disease: effects of long-term treatment on tumor mass in the experience of a single center
    Chiara Simeoli, Renata S. Auriemma, Fabio Tortora, Monica De Leo, Davide Iacuaniello, Alessia Cozzolino, Maria Cristina De Martino, Claudia Pivonello, Ciro Gabriele Mainolfi, Riccardo Rossi et al. · 2015 · Endocrine
  9. Preoperative Normalization of Cortisol Levels in Cushing's Disease After Medical Treatment: Consequences for Somatostatin and Dopamine Receptor Subtype Expression and In Vitro Response to Somatostatin Analogs and Dopamine Agonists
    Rob van der Pas, Richard Abraham Feelders, Federico Gatto, C. de Bruin, Alberto M. Pereira, P. M. van Koetsveld, D M Sprij-Mooij, A. Marlijn Waaijers, F. Dogan, Stefan Schulz et al. · 2013 · The Journal of Clinical Endocrinology & Metabolism
  10. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.
    L. Katznelson · 2013 · Journal of Clinical Endocrinology and Metabolism
  11. Quality of Life in Patients With Cushing's Disease
    Alicia Santos Vives, Eugenia Resmini, Maria-Antonia Martínez-Momblán, Elena Valassi, Luciana Martel‐Duguech, Susan M. Webb · 2019 · Frontiers in Endocrinology
  12. SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors
    Solène Castellnou, Alexandre Vasiljevic, V. Lapras, Véronique Raverot, Eudéline Alix, Françoise Borson‐Chazot, Emmanuel Jouanneau, Gérald Raverot, Hélène Lasolle · 2020 · Endocrine Connections
  13. EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis
    Takako Araki, Xiaohai Liu, Hiraku Kameda, Yukiko Tone, Hidenori Fukuoka, Masahide Tone, Shlomo K. Melmed · 2017 · Journal of the Endocrine Society
  14. ACTH Antagonists
    Clark, Adrian John, Forfar, Rachel, Hussain, Mashal, Jerman, Jeff, McIver, Ed, Taylor, Debra, Chan, Li · 2016 · Frontiers in Endocrinology
  15. The Expanding Role of Somatostatin Analogs in Gastroenteropancreatic and Lung Neuroendocrine Tumors
    M. Cives, J. Strosberg · 2015 · Drugs
  16. Cushing’s disease: the clinical features, diagnostics, differential diagnostics, and methods of treatment
    Galina Afanas'evna Mel'nichenko, Ivan Ivanovich Dedov, Zhanna E. Belaya, Liudmila Y. Rozhinskaya, Gulnar R. Vagapova, Н. И. Волкова, A Yu Grigor’ev, Elena Nikolaevna Grineva, Evgenia I. Marova, A M Mkrtumayn et al. · 2015 · Problems of Endocrinology
  17. Pasireotide for malignant insulinoma
    Amit Tirosh, Salomon Marcello Stemmer, Evgeny Solomonov, Eldad Elnekave, Wolfgang Saeger, Yelena Ravkin, Kobi Nir, Yeela Talmor‐Barkan, Ilan Shimon · 2015 · HORMONES
  18. Global clinical response in C ushing's syndrome patients treated with mifepristone
    Laurence J. Katznelson, D. Lynn Loriaux, David Feldman, Glenn David Braunstein, DAVID E. SCHTEINGART, Coleman Gross · 2013 · Clinical Endocrinology
  19. Pituitary Medicine From Discovery to Patient-Focused Outcomes
    Shlomo K. Melmed · 2016 · The Journal of Clinical Endocrinology & Metabolism
  20. Diabetes in Cushing Disease
    Gherardo Mazziotti, Annamaria Formenti, Stefano Frara, Filippo Maffezzoni, Mauro Doga, A. Giustina · 2017 · Current Diabetes Reports
  21. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
    G. Golor, K. Hu, M. Ruffin, A. Buchelt, E. Bouillaud, Yan-Feng Wang, M. Maldonado · 2012 · Drug Design, Development and Therapy
  22. Cushing's disease
    Nicholas A. Tritos, Beverly M. K. Biller · 2014 · Handbook of clinical neurology
  23. Clinicopathological correlates of adrenal Cushing's syndrome
    Kai Duan, Karen Hernandez, Özgür Mete · 2014 · Journal of Clinical Pathology
  24. Update on medical treatment for Cushing’s disease
    D. Cuevas-Ramos, D. Lim, M. Fleseriu · 2016 · Clinical Diabetes and Endocrinology
  25. The Adrenal Cortex
    Paul M. Stewart, Nils Peter Krone · 2011 · Elsevier eBooks
  26. Structure and Function of Somatostatin and Its Receptors in Endocrinology
    Bo Zhang, Xue Li, Zhe Bao Wu · 2024 · Endocrine Reviews
  27. New developments in the medical treatment of Cushing's syndrome
    Rob van der Pas, Wouter W. de Herder, Leo J. Hofland, Richard Abraham Feelders · 2012 · Endocrine Related Cancer
  28. The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
    Rosario Pivonello, Giorgio Arnaldi, Carla Maria Scaroni, Carla Santos de Souza Giordano, Salvatore Cannavò, Davide Iacuaniello, Laura Trementino, Marialuisa Zilio, Valentina Guarnotta, Adriana Albani et al. · 2019 · Endocrine
  29. The degree of urinary hypercortisolism is not correlated with the severity of cushing’s syndrome
    Valentina Guarnotta, Marco Calogero Amato, Rosario Pivonello, Giorgio Arnaldi, Alessandro Ciresi, Laura Trementino, Roberto Citarrella, Davide Iacuaniello, Grazia Michetti, Chiara Simeoli et al. · 2016 · Endocrine
  30. Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing’s syndrome and acromegaly
    Baroni, M. G., Giorgino, F., Pezzino, V., Scaroni, C., Avogaro, A. · 2016 · Journal of Endocrinological Investigation
  31. Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study
    Maria Fleseriu, Stephan Petersenn, Beverly M. K. Biller, Pınar Kadıoğlu, Christophe E.M. De Block, Guy G. T'Sjoen, Marie‐Christine Vantyghem, Libuse Tauchmanovà, Judi Wojna, Michael Roughton et al. · 2019 · Clinical Endocrinology
  32. Somatostatin and Somatostatin Receptors in Tumour Biology
    Ujendra Kumar · 2023 · International Journal of Molecular Sciences
  33. Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III Trial
    MacKenzie Feder, Jessica, Bourdeau, Isabelle, Vallette, Sophie, Beauregard, Hugues, Ste-Marie, Louis-Georges, Lacroix, André · 2014 · Pituitary
  34. Psychometric Evaluation of the Cushing’s Quality-of-Life Questionnaire
    Lauren M. Nelson, Anna Forsythe, Lori McLeod, Sonia J. Pulgar, Mario Maldonado, Theresa Coles, Yanqiong Zhang, Susan M. Webb, Xavier Costa Badia · 2013 · Patient
  35. Why We Should Still Treat by Neurosurgery Patients With Cushing Disease and a Normal or Inconclusive Pituitary MRI
    Justine Cristante, V. Lefournier, Nathalie Stürm, Jean Guy Passagia, Anne Sophie Gauchez, F. Tahon, Stéphane Cantin, Olivier Chabre, Emmanuel Gay · 2019 · The Journal of Clinical Endocrinology & Metabolism
  36. Update in the medical therapy of Cushing's disease
    Lynnette K. Nieman · 2013 · Current Opinion in Endocrinology Diabetes and Obesity
  37. Management and Medical Therapy of Mild Hypercortisolism
    Vittoria Favero, Arianna Cremaschi, Alberto Falchetti, Agostino Gaudio, Luigi Gennari, Alfredo Scillitani, Fabio Vescini, Valentina Morelli, Carmen Aresta, Iacopo Chiodini · 2021 · International Journal of Molecular Sciences
  38. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro
    Adriana Albani, Luis Gustavo Perez‐Rivas, Sicheng Tang, Julia Simon, Kristin Elisabeth Lucia, Paula Colón‐Bolea, Jochen Schopohl, Sigrun Roeber, Michael Buchfelder, Roman Rotermund et al. · 2022 · Endocrine Related Cancer
  39. Quality of Life and Other Outcomes in Children Treated for Cushing Syndrome
    Margaret F. Keil · 2013 · The Journal of Clinical Endocrinology & Metabolism
  40. Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression.
    M. Ruscica, M. Arvigo, L. Steffani, D. Ferone, P. Magni · 2013 · Current molecular medicine
  41. PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas
    Hadara Rubinfeld, Ilan Shimon · 2012 · Endocrine
  42. Cardiovascular risk and mortality in patients with active and treated hypercortisolism
    Li, Dingfeng, El Kawkgi, Omar M., Henriquez, Andres F., Bancos, Irina · 2020 · Gland Surgery
  43. Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.
    H. Dietrich, K. Hu, M. Ruffin, Dongweon Song, E. Bouillaud, Yan-Feng Wang, J. Hasskarl · 2012 · European Journal of Endocrinology
  44. Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta-analysis
    Rajan Palui, Jayaprakash Sahoo, Sadishkumar Kamalanathan, Sitanshu Sekhar Kar, Sandhiya Selvarajan, Harsh Durgia · 2018 · Journal of Endocrinological Investigation
  45. Therapeutic options after surgical failure in Cushing's disease: A critical review
    German Rubinstein, Andrea Oßwald, Stephanie Zopp, Katrin Ritzel, Marily Theodoropoulou, Felix Beuschlein, Martín Reincke · 2019 · Best Practice & Research Clinical Endocrinology & Metabolism
  46. The Interaction of Insulin and Pituitary Hormone Syndromes
    Marie Helene Schernthaner-Reiter, Peter S. Wolf, Greisa Vila, Anton Luger · 2021 · Frontiers in Endocrinology
  47. Safety and efficacy of pasireotide in dumping syndrome—results from a phase 2, multicentre study
    Jan F. Tack, Jens Aberle, Joris Arts, Martine Laville, Jean‐Michel Oppert, G. Bender, Sunil Bhoyrul, Tracey McLaughlin, T. Yoshikawa, Adrian Vella et al. · 2018 · Alimentary Pharmacology & Therapeutics
  48. Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
    Alessandro Mondin, Renzo Manara, Giacomo Voltan, Irene Tizianel, Luca Denaro, Marco Ferrari, Mattia Barbot, Carla Maria Scaroni, Filippo Ceccato · 2022 · Frontiers in Endocrinology
  49. Increased long‐term remission after adequate medical cortisol suppression therapy as presurgical treatment in C ushing's disease
    Oscar F. C. van den Bosch, Aline M.E. Stades, PIERRE M. J. ZELISSEN · 2013 · Clinical Endocrinology
  50. AIP and the somatostatin system in pituitary tumours
    Alejandro Ibáñez‐Costa, Márta Korbonits · 2017 · Journal of Endocrinology
  51. Updates in the Medical Treatment of Pituitary Adenomas
    Monica Livia Gheorghiu, Francesca A. Negreanu, Maria Fleseriu · 2019 · Hormone and Metabolic Research
  52. Somatostatin receptor expression and patients’ response to targeted medical treatment in pituitary tumors: evidences and controversies
    Federico Gatto, Marica Arvigo, Diego Ferone · 2020 · Journal of Endocrinological Investigation
  53. Individualized medical treatment options in Cushing disease
    Aleksandra Gilis‐Januszewska, Anna Bogusławska, Ewelina Rzepka, Witold Ziaja, Alicja Hubalewska–Dydejczyk · 2022 · Frontiers in Endocrinology
  54. Cushing's syndrome
    Eleni Daniel, John D C Newell-Price · 2013 · Medicine
  55. Cushing's disease: current medical therapies and molecular insights guiding future therapies
    Darryl Lau, Caleb Rutledge, Manish Kumar Aghi · 2015 · Neurosurgical FOCUS
  56. Pasireotide for the Prevention of Pancreatic Fistula Following Pancreaticoduodenectomy
    Nik Goyert, Gareth Eeson, Daniel Jonathan Kagedan, Ramy S. Behman, Madeline Lemke, Julie I. Hallet, Nicole Mittmann, Calvin Law, Paul Jack Karanicolas, Natalie G. Coburn · 2016 · Annals of Surgery
  57. Effectiveness of Medical Treatment of Cushing’s Disease: A Systematic Review and Meta-Analysis
    Julia Simões Corrêa Galendi, Afonso Nogueira Simões Correa Neto, Michelle R. Demetres, César Luiz Boguszewski, Vânia dos Santos Nunes Nogueira · 2021 · Frontiers in Endocrinology
  58. MRI–Negative Cushing's Disease: A Review on Therapeutic Management
    Mohammadmahdi Sabahi, Taha Shahbazi, Seyed Farzad Maroufi, Kevin Vidal, Pablo F. Recinos, Varun R. Kshettry, Florian Röser, Badih Adada, Hamid Borghei-Razavi · 2022 · World Neurosurgery
  59. Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review
    Ilan Shimon, Liat Rot, Edna Inbar · 2012 · Pituitary
  60. A pilot study of the effects of the somatostatin analog pasireotide in postoperative dumping syndrome
    Deloose, E., Bisschops, R., Holvoet, L., Arts, J., De Wulf, D., Caenepeel, P., Lannoo, M., Vanuytsel, T., Andrews, C., Tack, J. · 2014 · Neurogastroenterology & Motility
  61. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open‐label, phase I study
    Stephan Petersenn, Jens Bollerslev, Ayman M. Arafat, Jochen Schopohl, Omar Serri, Laurence J. Katznelson, Janet Lasher, Gareth Hughes, Ke Hu, George Shen et al. · 2014 · The Journal of Clinical Pharmacology
  62. Molecular basis of pharmacological therapy in Cushing’s disease
    Diego Ferone, Claudia Pivonello, Giovanni Vitale, Maria Chiara Zatelli, Annamaria Colao, Rosario Pivonello · 2013 · Endocrine
  63. Update on the management of recurrent Cushing's disease
    Martin J. Rutkowski, Patrick Michael Flanigan, Manish Kumar Aghi · 2015 · Neurosurgical FOCUS
  64. Aggressive Cushing’s Disease: Molecular Pathology and Its Therapeutic Approach
    Masaaki Yamamoto, Takahiro Nakao, Wataru Ogawa, Hidenori Fukuoka · 2021 · Frontiers in Endocrinology
  65. Pasireotide: A Review of Its Use in Cushing’s Disease
    Kate McKeage · 2013 · Drugs
  66. Mifepristone: is there a place in the treatment of Cushing’s disease?
    J. Carmichael, M. Fleseriu · 2013 · Endocrine
  67. Tumor-Directed Therapeutic Targets in Cushing Disease
    Marily Theodoropoulou, Martín Reincke · 2018 · The Journal of Clinical Endocrinology & Metabolism
  68. Pituitary Adenomas: What Are the Key Features? What Are the Current Treatments? Where Is the Future Taking Us?
    Domenico Solari, Rosario Pivonello, Chiara Caggiano, Elia Guadagno, Carmela Chiaramonte, Giovanni Miccoli, Luigi Maria Cavallo, Marialaura Del Basso De, Annamaria Colao, Paolo Cappabianca · 2019 · World Neurosurgery
  69. Pasireotide
    Richard Abraham Feelders, Uma Yasothan, Peter N. Kirkpatrick · 2012 · Nature Reviews Drug Discovery
  70. Medical Management of Persistent and Recurrent Cushing Disease
    Maria Fleseriu · 2012 · Neurosurgery Clinics of North America
  71. Endocrine Hypertension: A Practical Approach
    Joseph M Pappachan, Harit Buch · 2016 · Advances in experimental medicine and biology
  72. Pasireotide: A Novel Treatment for Tumor-Induced Hypoglycemia Due to Insulinoma and Non-Islet Cell Tumor Hypoglycemia
    Mahwash Fatima Siddiqui, Amy Vora, Sadia Ali, Jessica D. Abramowitz, Sasan Mirfakhraee · 2020 · Journal of the Endocrine Society
  73. Medical therapy in severe hypercortisolism
    Júlia Vieira Oberger Marques, César Luiz Boguszewski · 2021 · Best Practice & Research Clinical Endocrinology & Metabolism
  74. Phosphorylation of Threonine 333 Regulates Trafficking of the Human sst5 Somatostatin Receptor
    Aline Petrich, Anika Mann, Andrea Kliewer, Falko Nagel, Anne Strigli, Jan Carlo Märtens, Florian Pöll, Stefan Schulz · 2013 · Molecular Endocrinology
  75. Up-to 5-year efficacy of pasireotide in a patient with Cushing’s disease and pre-existing diabetes: literature review and clinical practice considerations
    Laura Trementino, Marina Cardinaletti, Carolina Concettoni, Giorgia Marcelli, Marco Boscaro, Giorgio Arnaldi · 2014 · Pituitary
  76. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues — Observations in two patients with acromegaly and severe headache
    Djordje Marina, Pia Burman, Marianne Klose, Olivera Casar‐Borota, Raul Miguel Luque, Justo Pastor Castano, Ulla Feldt‐Rasmussen · 2015 · Growth Hormone & IGF Research
  77. Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
    James W. Findling, Maria Fleseriu, John D C Newell-Price, Stephan Petersenn, Rosario Pivonello, Albert Kandra, Alberto M Pedroncelli, Beverly M. K. Biller · 2016 · Endocrine
  78. Treatment of Cushing Disease With Pituitary-Targeting Seliciclib
    Ning‐Ai Liu, Anat Ben-Shlomo, John David Carmichael, Christina Wang, Ronald S. Swerdloff, Anthony P. Heaney, Garni Barkhoudarian, Daniel F. Kelly, Mazen Noureddin, Lin Lü et al. · 2022 · The Journal of Clinical Endocrinology & Metabolism
  79. Variability in laboratory parameters used for management of Cushing’s syndrome
    Francesca Pecori Giraldi, Alberto Giacinto Ambrogio · 2015 · Endocrine
  80. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis
    Merima Herac, Bruno Niederle, Markus Raderer, Michael Krebs, Klaus Kaserer, Oskar Koperek · 2016 · Apmis
  81. E2F1-mediated human POMC expression in ectopic Cushing’s syndrome
    Takako Araki, Ning‐Ai Liu, Yukiko Tone, Daniel Cuevas Ramos, Roy Heltsley, Masahide Tone, Shlomo K. Melmed · 2016 · Endocrine Related Cancer
  82. A prospective longitudinal study of Pasireotide in Nelson’s syndrome
    Eleni Daniel, Miguel Debono, Sharon Caunt, Constantine Girio-Fragkoulakis, Stephen J. Walters, Scott Alexander Akker, Ashley Barry Grossman, Peter James Trainer, John D C Newell-Price · 2018 · Pituitary
  83. Medical Treatment of Cushing Disease
    Maria Fleseriu · 2014 · Endocrinology and Metabolism Clinics of North America
  84. Cushing’s syndrome: an update on current pharmacotherapy and future directions
    Sara G Creemers, Leo J. Hofland, Steven W. J. Lamberts, Richard Abraham Feelders · 2015 · Expert Opinion on Pharmacotherapy
  85. Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial
    Baljit Singh, Julia Anne Smith, Deborah Axelrod, Pietro Ameri, Heather Levitt, Ann Danoff, MARTIN L. LESSER, Cristina de Angelis, Irineu Illa-Bochaca, Sara E. Lubitz et al. · 2014 · Breast Cancer Research
  86. Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease
    Susan M. Webb, John E. Ware, Anna Forsythe, Min Yang, Xavier Costa Badia, Lauren M. Nelson, James Signorovitch, Lori McLeod, Mario Maldonado, Wojciech Zgliczyński et al. · 2014 · European Journal of Endocrinology
  87. Recent Progress in the Medical Therapy of Pituitary Tumors
    Fabienne Langlois, Shirley McCartney, Maria Fleseriu · 2017 · Endocrinology and Metabolism
  88. Aace/Ace Disease State Clinical Review: Diagnosis and Management of Midgut Carcinoids
    Eric H. Liu, Carmen C. Solórzano, Laurence J. Katznelson, Aaron I. Vinik, Richard J. Wong, Gregory William Randolph · 2015 · Endocrine Practice
  89. A Single-Center 10-Year Experience with Pasireotide in Cushing’s Disease: Patients’ Characteristics and Outcome
    Laura Trementino, Grazia Michetti, Alessia Angeletti, Giorgia Marcelli, Carolina Concettoni, C. Cardinaletti, Barbara Polenta, Marco Boscaro, Giorgio Arnaldi · 2016 · Hormone and Metabolic Research
  90. Medical management of Cushing’s disease
    Nicholas A. Tritos, Beverly M. K. Biller · 2013 · Journal of Neuro-Oncology
  91. Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression
    G. Walls, M. Stevenson, B. Soukup, K. Lines, A. Grossman, H. Schmid, R. Thakker · 2016 · Endocrinology
  92. Pituitary Masses and Tumors
    Shlomo K. Melmed, David L. Kleinberg · 2016 · Elsevier eBooks
  93. An Individualized Approach to the Evaluation of Cushing Syndrome
    Susmeeta T. Sharma · 2017 · Endocrine Practice
  94. Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study
    Rosario Pivonello, Atanaska P. Elenkova, Maria Fleseriu, Richard Abraham Feelders, Przemysław Witek, Yona Greenman, Eliza Brevoort Geer, Paola Perotti, Leonard Saiegh, Fredric J. Cohen et al. · 2021 · Frontiers in Endocrinology
  95. New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy
    Maria Fleseriu, Stephan Petersenn · 2013 · Journal of Neuro-Oncology
  96. Effects of anti-somatostatin agents on glucose metabolism
    Bruno L Vergès · 2017 · Diabetes & Metabolism
  97. AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease
    Amir Hekmat Hamrahian, Kevin C.J. Yuen, Andrew R. Hoffman · 2014 · Endocrine Practice
  98. Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects
    Gherardo Mazziotti, Alessandra Mosca, Stefano Frara, Giovanni Vitale, Andrea Giustina · 2017 · Expert Opinion on Pharmacotherapy
  99. Pasireotide treatment significantly reduces tumor volume in patients with Cushing’s disease: results from a Phase 3 study
    André Lacroix, Feng Gu, Jochen Schopohl, Albert Kandra, Alberto M Pedroncelli, Lixian Jin, Rosario Pivonello · 2019 · Pituitary
  100. Long-acting pasireotide improves clinical signs and quality of life in Cushing’s disease: results from a phase III study
    André Lacroix, Marcello D. Bronstein, Jochen Schopohl, Tuncay Delibaşı, Roberto Salvatori, Y. Li, Ariel Barkan, N. Suzaki, Libuse Tauchmanovà, Christine-Elke Ortmann et al. · 2020 · Journal of Endocrinological Investigation